» Articles » PMID: 39012004

Use of Cannabinoids by People Who Consume Kratom in the United States

Overview
Journal J Addict Med
Specialty Psychiatry
Date 2024 Jul 16
PMID 39012004
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: To estimate lifetime, past-year, and past-month prevalence of kratom, cannabis, and cannabidiol-only product use among adults 18 years and older in the United States, using 2 independent datasets.

Methods: Utilizing ( a ) the 2022 National Survey on Drug Use and Health (NSDUH) and ( b ) a 2022 online national convenience sample of adults who use kratom regularly (from our research group at the National Institute on Drug Abuse [NIDA]), we examined key demographic information as well as lifetime, past-year, and past-month substance use and preferences.

Results: Among the full sample of adults from the 2022 NSDUH, the prevalence of lifetime use was 49.69% for cannabis, 34.09% for cannabidiol-only products, and 1.93% for kratom. When solely examining participants who have used kratom, both independent datasets showed higher proportions of cannabis use over the lifetime-92.81% (95% confidence interval: 90.31-95.31) in the NSDUH subset and 92.16% (95% confidence interval: 89.37-94.95) in our NIDA sample.

Conclusions: Our study demonstrates that people are co-using kratom with cannabis and/or cannabidiol-only products at the same time or during the same time period, though more research is needed to understand people's motivations and practices for such co-use. Co-use might result in herb-herb interactions that may impact research findings and clinical outcomes for people who use kratom.

Citing Articles

Controversies in Assessment, Diagnosis, and Treatment of Kratom Use Disorder.

Smith K, Epstein D, Weiss S Curr Psychiatry Rep. 2024; 26(9):487-496.

PMID: 39134892 PMC: 11344726. DOI: 10.1007/s11920-024-01524-1.